 Advertisement | ||||||||
 | ||||||||
|
||||||||
 |
 |
 |
 |
 |
 |
 |
||
|
Dr. Kalant is Professor Emeritus, Department of Pharmacology, University of Toronto, and Addiction Research Foundation Division, Centre for Addiction and Mental Health, Toronto, Ont.
Correspondence to: Dr. H. Kalant, Department of Pharmacology, Medical Sciences Building, University of Toronto, Toronto ON M5S 1A8; fax 416 978-6395; harold.kalant{at}utoronto.ca
Abstract
Abtract"ECSTASY" (MDMA) AND RELATED DRUGS ARE AMPHETAMINE DERIVATIVES that also have some of the pharmacological properties of mescaline. They have become popular with participants in "raves," because they enhance energy, endurance, sociability and sexual arousal. This vogue among teenagers and young adults, together with the widespread belief that "ecstasy" is a safe drug, has led to a thriving illicit traffic in it. But these drugs also have serious toxic effects, both acute and chronic, that resemble those previously seen with other amphetamines and are caused by an excess of the same sympathomimetic actions for which the drugs are valued by the users. Neurotoxicity to the serotonergic system in the brain can also cause permanent physical and psychiatric problems. A detailed review of the literature has revealed over 87 "ecstasy"-related fatalities, caused by hyperpyrexia, rhabdomyolysis, intravascular coagulopathy, hepatic necrosis, cardiac arrhythmias, cerebrovascular accidents, and drug-related accidents or suicide. The toxic or even fatal dose range overlaps the range of recreational dosage. The available evidence does not yet permit an accurate assessment of the size of the problem presented by the use of these drugs.
This article has been cited by other articles:
|
|
 |
|
  A. E. Schwaninger, M. R. Meyer, J. Zapp, and H. H. Maurer The Role of Human UDP-Glucuronyltransferases on the Formation of the Methylenedioxymethamphetamine (Ecstasy) Phase II Metabolites R- and S-3-Methoxymethamphetamine 4-O-Glucuronides Drug Metab. Dispos., November 1, 2009; 37(11): 2212 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Meyer, F. T. Peters, and H. H. Maurer The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers Drug Metab. Dispos., June 1, 2009; 37(6): 1152 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Zimmerman Poisonings and Overdoses ACCP Crit Care Med Brd Rev, January 1, 2009; 20(0): 341 - 356. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Meyer, F. T. Peters, and H. H. Maurer The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers Drug Metab. Dispos., November 1, 2008; 36(11): 2345 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. T. Peters, N. Samyn, T. Kraemer, W. J. Riedel, and H. H. Maurer Negative-Ion Chemical Ionization Gas Chromatography-Mass Spectrometry Assay for Enantioselective Measurement of Amphetamines in Oral Fluid: Application to a Controlled Study with MDMA and Driving Under the Influence Cases Clin. Chem., April 1, 2007; 53(4): 702 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C.M. Brust Seizures and substance abuse: Treatment considerations Neurology, December 26, 2006; 67(12_suppl_4): S45 - S48. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. W. Freudenmann, C. Schonfeldt-Lecuona, M. Spitzer, L. Hermle, and G. Gron Electroconvulsive therapy in the treatment of depression in a former ecstasy user J Psychopharmacol, November 1, 2006; 20(6): 860 - 862. [Abstract] [PDF]
|
|
|
|
|
|
K. Wolff, E. M. Tsapakis, A. R. Winstock, D. Hartley, D. Holt, M. L. Forsling, and K. J. Aitchison Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population J Psychopharmacol, May 1, 2006; 20(3): 400 - 410. [Abstract] [PDF]
|
|
|
|
 |
|
 W. Jeng, A. Ramkissoon, T. Parman, and P. G. Wells Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration FASEB J, April 1, 2006; 20(6): 638 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. T. Peters, N. Samyn, C. T.J. Lamers, W. J. Riedel, T. Kraemer, G. de Boeck, and H. H. Maurer Drug Testing in Blood: Validated Negative-Ion Chemical Ionization Gas Chromatographic-Mass Spectrometric Assay for Enantioselective Measurement of the Designer Drugs MDEA, MDMA, and MDA and Its Application to Samples from a Controlled Study with MDMA Clin. Chem., October 1, 2005; 51(10): 1811 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pifl, G. Nagy, S. Berenyi, A. Kattinger, H. Reither, and S. Antus Pharmacological Characterization of Ecstasy Synthesis Byproducts with Recombinant Human Monoamine Transporters J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Wynn, K. L. Cozza, M. J. Zapor, G. W. Wortmann, and S. C. Armstrong Antiretrovirals, Part III: Antiretrovirals and Drugs of Abuse Psychosomatics, February 1, 2005; 46(1): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Parrott Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy J Psychopharmacol, January 1, 2005; 19(1): 71 - 83. [Abstract] [PDF]
|
|
|
|
 |
|
 P. L. Brown, R. A. Wise, and E. A. Kiyatkin Brain Hyperthermia Is Induced by Methamphetamine and Exacerbated by Social Interaction J. Neurosci., May 1, 2003; 23(9): 3924 - 3929. [Abstract] [Full Text] [PDF]
|
|
| HOME | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | HELP | SEARCH |
|
|||||
|
Copyright 1995-2001, Canadian Medical Association. All rights reserved. ISSN 1488-2329
(e) 0820-3946 (p)
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association. |
|||||
